T-cell-based therapies for malignancy and infection in childhood

Pediatric Clinics of North America

Volumn 57, Issue 1, 2010, Pages 83-96

  Ahmed, Nabil ^a   Heslop, Helen E ^a   Mackall, Crystal L ^b  

^a CENTER FOR CELL AND GENE THERAPY   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Adoptive immunotherapy; Chimeric antigen receptor; Hematopoietic stem cell transplantation; Immune reconstitution; Lymphopenia; Pediatrics; Tumor antigens; Tumor vaccines

Indexed keywords

CANCER VACCINE; DENDRITIC CELL VACCINE; DNA VACCINE; PEPTIDE VACCINE; PLACEBO; TUMOR ANTIGEN;

ADENOVIRUS; ADOPTIVE IMMUNOTHERAPY; ANTIGEN EXPRESSION; B LYMPHOCYTE; CELL THERAPY; CHILDHOOD CANCER; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CYTOMEGALOVIRUS; DISEASE MODEL; DRUG EFFICACY; DRUG SAFETY; EPSTEIN BARR VIRUS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEPATITIS B VIRUS; HUMAN; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNOTHERAPY; LYMPHOCYTE TRANSFUSION; LYMPHOCYTOPENIA; NONHUMAN; PROSTATE CANCER; REVIEW; T LYMPHOCYTE; VIRUS INFECTION; WART VIRUS;

ADOPTIVE TRANSFER; CHILD; HUMANS; INFECTION; NEOPLASMS; T-LYMPHOCYTES; TREATMENT OUTCOME; VACCINES;

EID: 77951071901     PISSN: 00313955     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pcl.2009.11.002     Document Type: Review

References (72)

1. O'Reilly R.J., Doubrovina E., Trivedi D., et al. Adoptive transfer of antigen-specific T-cells of donor type for immunotherapy of viral infections following allogeneic hematopoietic cell transplants. Immunol Res 2007, 38(1-3):237-250.
2. Scanlan M.J., Gure A.O., Jungbluth A.A., et al. Cancer/testis antigens: an expanding family of targets for cancer immunotherapy. Immunol Rev 2002, 188:22-32.
3. Scarcella D.L., Chow C.W., Gonzales M.F., et al. Expression of MAGE and GAGE in high-grade brain tumors: a potential target for specific immunotherapy and diagnostic markers. Clin Cancer Res 1999, 5(2):335-341.
4. Sahin U., Koslowski M., Tureci O., et al. Expression of cancer testis genes in human brain tumors. Clin Cancer Res 2000, 6(10):3916-3922.
5. Cheung I.Y., Cheung N.K. Molecular detection of GAGE expression in peripheral blood and bone marrow: utility as a tumor marker for neuroblastoma. Clin Cancer Res 1997, 3(5):821-826.
6. Greiner J., Ringhoffer M., Taniguchi M., et al. mRNA expression of leukemia-associated antigens in patients with acute myeloid leukemia for the development of specific immunotherapies. Int J Cancer 2004, 108(5):704-711.
7. Liu X.F., Helman L.J., Yeung C., et al. XAGE-1, a new gene that is frequently expressed in Ewing's sarcoma. Cancer Res 2000, 60(17):4752-4755.
8. Rodolfo M., Luksch R., Stockert E., et al. Antigen-specific immunity in neuroblastoma patients: antibody and T-cell recognition of NY-ESO-1 tumor antigen. Cancer Res 2003, 63(20):6948-6955.
9. Soling A., Schurr P., Berthold F. Expression and clinical relevance of NY-ESO-1, MAGE-1 and MAGE-3 in neuroblastoma. Anticancer Res 1999, 19(3B):2205-2209.
10. Li C.M., Guo M., Borczuk A., et al. Gene expression in Wilms' tumor mimics the earliest committed stage in the metanephric mesenchymal-epithelial transition. Am J Pathol 2002, 160(6):2181-2190.
11. Oberthuer A., Hero B., Spitz R., et al. The tumor-associated antigen PRAME is universally expressed in high-stage neuroblastoma and associated with poor outcome. Clin Cancer Res 2004, 10(13):4307-4313.
12. Steinbach D., Hermann J., Viehmann S., et al. Clinical implications of PRAME gene expression in childhood acute myeloid leukemia. Cancer Genet Cytogenet 2002, 133(2):118-123.
13. Sarkar A.K., Nuchtern J.G. Lysis of MYCN-amplified neuroblastoma cells by MYCN peptide-specific cytotoxic T lymphocytes. Cancer Res 2000, 60(7):1908-1913.
14. Sarkar A.K., Burlingame S.M., Zang Y.Q., et al. Major histocompatibility complex-restricted lysis of neuroblastoma cells by autologous cytotoxic T lymphocytes. J Immunother 2001, 24(4):305-311.
15. Molldrem J.J., Lee P.P., Wang C., et al. Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nat Med 2000, 6(9):1018-1023.
16. Molldrem J. Immune therapy of AML. Cytotherapy 2002, 4(5):437-438.
17. Sugiyama H. Cancer immunotherapy targeting WT1 protein. Int J Hematol 2002, 76(2):127-132.
18. Oka Y., Tsuboi A., Elisseeva O.A., et al. WT1 as a novel target antigen for cancer immunotherapy. Curr Cancer Drug Targets 2002, 2(1):45-54.
19. Andersen M.H., Thor S.P. Survivin-a universal tumor antigen. Histol Histopathol 2002, 17(2):669-675.
20. Gordan J.D., Vonderheide R.H. Universal tumor antigens as targets for immunotherapy. Cytotherapy 2002, 4(4):317-327.
21. Altieri D.C. Validating survivin as a cancer therapeutic target. Nat Rev Cancer 2003, 3(1):46-54.
22. Vonderheide R.H., Hahn W.C., Schultze J.L., et al. The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes. Immunity 1999, 10(6):673-679.
23. Vonderheide R.H., Domchek S.M., Schultze J.L., et al. Vaccination of cancer patients against telomerase induces functional antitumor CD8+ T lymphocytes. Clin Cancer Res 2004, 10(3):828-839.
24. Worley B.S., van den Broeke L.T., Goletz T.J., et al. Antigenicity of fusion proteins from sarcoma-associated chromosomal translocations. Cancer Res 2001, 61(18):6868-6875.
25. Yotnda P., Firat H., Garcia-Pons F., et al. Cytotoxic T cell response against the chimeric p210 BCR-ABL protein in patients with chronic myelogenous leukemia. J Clin Invest 1998, 101(10):2290-2296.
26. Yotnda P., Garcia F., Peuchmaur M., et al. Cytotoxic T cell response against the chimeric ETV6-AML1 protein in childhood acute lymphoblastic leukemia. J Clin Invest 1998, 102(2):455-462.
27. van den Broeke L.T., Pendleton C.D., Mackall C., et al. Identification and epitope enhancement of a PAX-FKHR fusion protein breakpoint epitope in alveolar rhabdomyosarcoma cells created by a tumorigenic chromosomal translocation inducing CTL capable of lysing human tumors. Cancer Res 2006, 66(3):1818-1823.
28. Yanuck M., Carbone D.P., Pendleton C.D., et al. A mutant p53 tumor suppressor protein is a target for peptide-induced CD8+ cytotoxic T cells. Cancer Res 1993, 53:3257-3261.
29. Maher V.E., Worley B.S., Contois D., et al. Mutant oncogene and tumor suppressor gene products and fusion proteins created by chromosomal translocations as targets for cancer vaccines. Peptide based cancer vaccines 2000, Landes Biosciences, Austin, TX. Georgetown (TX), p.17-39.
30. Radvanyi L. Discovery and immunologic validation of new antigens for therapeutic cancer vaccines. Int Arch Allergy Immunol 2004, 133(2):179-197.
31. Roskrow M.A., Suzuki N., Gan Y., et al. Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the treatment of patients with EBV-positive relapsed Hodgkin's disease. Blood 1998, 91(8):2925-2934.
32. Bollard C.M., Straathof K.C., Huls M.H., et al. The generation and characterization of LMP2-specific CTLs for use as adoptive transfer from patients with relapsed EBV-positive Hodgkin disease. J Immunother 2004, 27(4):317-327.
33. Rosenberg S.A., Yang J.C., Restifo N.P. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004, 10(9):909-915.
34. Dazzi F., Szydlo R.M., Goldman J.M. Donor lymphocyte infusions for relapse of chronic myeloid leukemia after allogeneic stem cell transplant: where we now stand. Exp Hematol 1999, 27(10):1477-1486.
35. Finke L.H., Wentworth K., Blumenstein B., et al. Lessons from randomized phase III studies with active cancer immunotherapies-outcomes from the 2006 meeting of the Cancer Vaccine Consortium (CVC). Vaccine 2007, 25(Suppl 2):B97-109.
36. Kennedy-Nasser A.A., Brenner M.K. T-cell therapy after hematopoietic stem cell transplantation. Curr Opin Hematol 2007, 14(6):616-624.
37. Feuchtinger T., Matthes-Martin S., Richard C., et al. Safe adoptive transfer of virus-specific T-cell immunity for the treatment of systemic adenovirus infection after allogeneic stem cell transplantation. Br J Haematol 2006, 134(1):64-76.
38. Gerdemann U., Christin A.S., Vera J.F., et al. Nucleofection of DCs to generate multivirus-specific T cells for prevention or treatment of viral infections in the immunocompromised host. Mol Ther 2009, 17(9):1616-1625.
39. Heslop H.E. How I treat EBV lymphoproliferation. Blood 2009, 114(19):4002-4008.
40. Leen A.M., Christin A., Myers G.D., et al. Cytotoxic T lymphocyte therapy with donor T cells prevents and treats adenovirus and Epstein-Barr virus infections after haploidentical and matched unrelated stem cell transplant. Blood 2009, 114(19):4283-4292.
41. Leen A.M., Myers G.D., Sili U., et al. Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals. Nat Med 2006, 12(10):1160-1166.
42. Perruccio K., Tosti A., Burchielli E., et al. Transferring functional immune responses to pathogens after haploidentical hematopoietic transplantation. Blood 2005, 106(13):4397-4406.
43. Walter E.A., Greenberg P.D., Gilbert M.J., et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med 1995, 333(16):1038-1044.
44. Cobbold M., Khan N., Pourgheysari B., et al. Adoptive transfer of cytomegalovirus-specific CTL to stem cell transplant patients after selection by HLA-peptide tetramers. J Exp Med 2005, 202(3):379-386.
45. Heslop HE SK, Pule MA et al. Long term outcome of EBV specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood. [Epub ahead of print].
46. Einsele H., Roosnek E., Rufer N., et al. Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy. Blood 2002, 99(11):3916-3922.
47. Peggs K.S., Verfuerth S., Pizzey A., et al. Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell lines. Lancet 2003, 362(9393):1375-1377.
48. Haque T., Wilkie G.M., Jones M.M., et al. Allogeneic cytotoxic T-cell therapy for EBV-positive post-transplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial. Blood 2007, 110(4):1123-1131.
49. Jedema I., Meij P., Steeneveld E., et al. Early detection and rapid isolation of leukemia-reactive donor T cells for adoptive transfer using the IFN-gamma secretion assay. Clin Cancer Res 2007, 13(2 Pt 1):636-643.
50. Rooney C.M., Smith C.A., Ng C.Y., et al. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood 1998, 92(5):1549-1555.
51. Bollard C.M., Aguilar L., Straathof K.C., et al. Cytotoxic T lymphocyte therapy for Epstein-Barr virus+ Hodgkin's disease. J Exp Med 2004, 200(12):1623-1633.
52. Louis C.U., Straathof K., Bollard C.M., et al. Enhancing the in vivo expansion of adoptively transferred EBV-specific CTL with lymphodepleting CD45 monoclonal antibodies in NPC patients. Blood 2009, 113(11):2442-2450.
53. Bollard C.M., Gottschalk S., Leen A.M., et al. Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer. Blood 2007, 110(8):2838-2845.
54. Falkenburg J.H., Wafelman A.R., Joosten P., et al. Complete remission of accelerated phase chronic myeloid leukemia by treatment with leukemia-reactive cytotoxic T lymphocytes. Blood 1999, 94(4):1201-1208.
55. Porter D.L., Levine B.L., Bunin N., et al. A phase 1 trial of donor lymphocyte infusions expanded and activated ex vivo via CD3/CD28 co-stimulation. Blood 2006, 107(4):1325-1331.
56. Sadelain M., Riviere I., Brentjens R. Targeting tumours with genetically enhanced T lymphocytes. Nat Rev Cancer 2003, 3(1):35-45.
57. Eshhar Z., Waks T., Gross G., et al. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc Natl Acad Sci U S A 1993, 90(2):720-724.
58. Ahmed N., Ratnayake M., Savoldo B., et al. Regression of experimental medulloblastoma following transfer of HER2-specific T cells. Cancer Res 2007, 67(12):5957-5964.
59. Pule M.A., Savoldo B., Myers G.D., et al. Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and anti-tumor activity in individuals with neuroblastoma. Nat Med 2008, 14(11):1264-1270.
60. Till B.G., Jensen M.C., Wang J., et al. Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells. Blood 2008, 112(6):2261-2271.
61. Klebanoff C.A., Gattinoni L., Torabi-Parizi P., et al. Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells. Proc Natl Acad Sci U S A 2005, 102(27):9571-9576.
62. Haynes B.F., Sempowski G.D., Wells A.F., et al. The human thymus during aging. Immunol Res 2000, 22(2-3):253-261.
63. Mackall C.L., Fleisher T.A., Brown M.R., et al. Age, thymopoiesis, and CD4+ T-lymphocyte regeneration after intensive chemotherapy. N Engl J Med 1995, 332(3):143-149.
64. Hakim F.T., Memon S.A., Cepeda R., et al. Age-dependent incidence, time course, and consequences of thymic renewal in adults. J Clin Invest 2005, 115(4):930-939.
65. Weinberg K., Blazar B.R., Wagner J.E., et al. Factors affecting thymic function after allogeneic hematopoietic stem cell transplantation. Blood 2001, 97(5):1458-1466.
66. Mackall C.L., Bare C.V., Granger L.A., et al. Thymic-independent T cell regeneration occurs via antigen-driven expansion of peripheral T cells resulting in a repertoire that is limited in diversity and prone to skewing. J Immunol 1996, 156(12):4609-4616.
67. Surh C.D., Sprent J. Regulation of mature T cell homeostasis. Semin Immunol 2005, 17(3):183-191.
68. Fry T.J., Mackall C.L. The many faces of IL-7: from lymphopoiesis to peripheral T cell maintenance. J Immunol 2005, 174(11):6571-6576.
69. Guimond M., Veenstra R.G., Grindler D.J., et al. Interleukin 7 signaling in dendritic cells regulates the homeostatic proliferation and niche size of CD4+ T cells. Nat Immunol 2009, 10(2):149-157.
70. Sportes C., Hakim F.T., Memon S.A., et al. Administration of rhIL-7 in humans increases in vivo TCR repertoire diversity by preferential expansion of naive T cell subsets. J Exp Med 2008, 205(7):1701-1714.
71. Cui Y., Zhang H., Meadors J., et al. Harnessing the physiology of lymphopenia to support adoptive immunotherapy in lymphoreplete hosts. Blood 2009.
72. Mackall C.L., Rhee E.H., Read E.J., et al. A pilot study of consolidative immunotherapy in patients with high-risk pediatric sarcomas. Clin Cancer Res 2008, 14(15):4850-4858.